BioMerieuxLTS:0RUG +2.10%71 EBITDA Margin % is 17.09% as of Dec. 2025, which is 19% below its 10-year median of 21.13. GuruFocus rates LTS:0RUG with a GF Score™ of 71/100 and a GF Value™ of €109.78 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BioMerieux ranks better than 75.49% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioMerieux's EBITDA for the
six
months ended in Dec. 2025 was €346 Mil. BioMerieux's Revenue for the
six
months ended in Dec. 2025 was €2,026 Mil. Therefore, BioMerieux's EBITDA margin for the quarter that ended in Dec. 2025 was 17.09%.
BioMerieux (LTS:0RUG) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioMerieux EBITDA Margin % Related Terms
BioMerieux EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BioMerieux's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RUG vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, BioMerieux's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMerieux EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BioMerieux's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioMerieux's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMerieux (LTS:0RUG) has a EBITDA Margin % of 17.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioMerieux and its competitors. This is 19% below median its historical median of 21.13. Over the past decade, BioMerieux's EBITDA Margin % has ranged from 19.38 to 30.55. According to the industry distribution chart, BioMerieux ranks #50 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 24.5%.
Is BioMerieux's EBITDA Margin % too high?
BioMerieux's current EBITDA Margin % of 17.09% is 19% below median its 10-year median of 21.13. Over the past 10 years, this metric has ranged from a low of 19.38 to a high of 30.55. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. BioMerieux's value of 17.09% is 228.7% above this industry median. Based on the distribution chart, BioMerieux ranks #50 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BioMerieux has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BioMerieux ranks #50 out of 204 companies for EBITDA Margin %. This places BioMerieux in the top 25% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. BioMerieux's value of 17.09% is 228.7% above this benchmark. Historically, BioMerieux's own EBITDA Margin % has ranged from 19.38 to 30.55 over the past decade. While the company's 10-year median is 21.13 vs. the industry median of 5.20, BioMerieux has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioMerieux's current EBITDA Margin % of 17.09% is 228.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioMerieux and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioMerieux's current EBITDA Margin % is 17.09%, which is 19% below median its own 10-year median of 21.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (LTS:0RUG) is currently considered Significantly Undervalued. The stock's GF Value™ is €109.78, compared to a current price of €67.95 — trading 38.1% below its estimated fair value. The current EBITDA Margin % is 17.09%, which is 19% below median its 10-year median of 21.13 and 228.7% above the Medical Diagnostics & Research industry median of 5.20. BioMerieux's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioMerieux (LTS:0RUG), the current EBITDA Margin % is 17.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMerieux (LTS:0RUG) Overvalued in 2026?
Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued.
The current stock price of €67.95 is trading 38.1% below its estimated GF Value™ of €109.78.
GuruFocus considers BioMerieux to be Significantly Undervalued.
Key valuation signals for LTS:0RUG:
EBITDA Margin %: 17.09% (19% below median its 10-year median of 21.13)
GF Value™: €109.78 vs. price of €67.95 (38.1% below fair value)
Industry Position: 228.7% above the Medical Diagnostics & Research median (#50 of 204)
No single metric tells the full story. See the LTS:0RUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
71GF Score
Get the complete analysis for LTS:0RUG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RUG has been successfully added to your 
